JAMA Dermatology

<jats:sec id="ab-doi240066-4"><jats:title>Importance</jats:title><jats:p>Isotretinoin is the only medical acne treatment capable of inducing acne remission; however, some patients experience acne relapse and require retrials of isotretinoin. There is a need to understand who is most at risk and how daily dose and cumulative dosage can influence outcomes.</jats:p></jats:sec><jats:sec id="ab-doi240066-5"><jats:title>Objective</jats:title><jats:p>To assess rates of acne relapse and isotretinoin retrial and to identify associated factors among patients with acne who received an isotretinoin treatment course.</jats:p></jats:sec><jats:sec id="ab-doi240066-6"><jats:title>Design, Setting, and Participants</jats:title><jats:p>This cohort study used data from the MarketScan commercial claims database from January 1, 2017, to December 31, 2020, to identify patients with acne who were 12 years or older and had received isotretinoin for 4 months or longer, with at least 1 year of continuous enrollment after completion of isotretinoin. Data analyses were performed from June 30, 2024, to August 1, 2024.</jats:p></jats:sec><jats:sec id="ab-doi240066-7"><jats:title>Main Outcomes and Measures</jats:title><jats:p>Multivariable Cox proportional hazards regression was used to quantify associations of patient demographic and treatment characteristics with acne relapse and isotretinoin retrial.</jats:p></jats:sec><jats:sec id="ab-doi240066-8"><jats:title>Results</jats:title><jats:p>A total of 19 907 patients (mean [SD] age, 20.6 [7.8] years; 10 504 females [52.8%]) were included, among whom 4482 (22.5%) had acne relapse and 1639 (8.2%) had isotretinoin retrial. Female sex (hazard ratio [HR], 1.43; 95% CI, 1.35-1.52) was significantly associated with increased rates of acne relapse, and isotretinoin cumulative dosage (mg/kg) was associated with a decreased rate of acne relapse (HR, 0.996; 95% CI, 0.995-0.997). Furthermore, daily dose was not associated with decreased risk of acne relapse or isotretinoin retrial among those with conventional and high cumulative dosages. Female sex (HR, 0.68; 95% CI, 0.62-0.76) and isotretinoin cumulative dosage (HR, 0.99; 95% CI, 0.98-0.99) were associated with decreased rates of isotretinoin retrial. Stratification by cumulative dosage indicated that higher cumulative dosage was associated with decreased rates of retrial among patients with low (&amp;amp;lt;120 mg/kg) and conventional (120-220 mg/kg), but not high (&amp;amp;gt;220 mg/kg) cumulative dosage. Maximum daily dose (mg/kg/d) was not negatively associated with acne relapse or isotretinoin retrial in patients with cumulative dosage of 120 mg/kg or more.</jats:p></jats:sec><jats:sec id="ab-doi240066-9"><jats:title>Conclusions and Relevance</jats:title><jats:p>The findings of this cohort study suggest that higher cumulative dosage may potentially reduce risk of acne relapse and isotretinoin retrial. Furthermore, daily dose was not associated with decreased risk of the outcomes for conventional and high cumulative dosage; therefore, daily dosing could be individualized to patient goals and preferences.</jats:p></jats:sec>

Guidelines of care for the management of acne vulgaris.

J Am Acad Dermatol

Adverse effects of isotretinoin: a retrospective review of 1743 patients started on isotretinoin.

Australas J Dermatol

Remission rates in acne patients treated with various doses of 13-cis-retinoic acid (isotretinoin).

Br J Dermatol

Isotretinoin for the treatment of acne vulgaris: which factors may predict the need for more than one course?

Isotretinoin for acne vulgaris–10 years later: a safe and successful treatment.

Recurrence rates after the first course of isotretinoin.

Arch Dermatol

Predictive factors for failure of isotretinoin treatment in acne patients: results from a cohort of 237 patients.

Dermatology

Isotretinoin in acne vulgaris: a prospective analysis of 160 cases from Kuwait.

J Drugs Dermatol

Prospective study of risk factors of relapse after treatment of acne with oral isotretinoin.

Isotretinoin therapy and the incidence of acne relapse: a nested case-control study.

Relapse of acne following isotretinoin treatment: a retrospective study of 405 patients.

The relapses of cystic acne after isotretinoin treatment are age-related: a long-term follow-up study.

Dermatologica

Low-cumulative dose isotretinoin treatment in mild-to-moderate acne: efficacy in achieving stable remission.

J Eur Acad Dermatol Venereol

Could higher doses of isotretinoin reduce the frequency of treatment failure in patients with acne?

High-dose isotretinoin treatment and the rate of retrial, relapse, and adverse effects in patients with acne vulgaris.

JAMA Dermatol

Acne relapse rate and predictors of relapse following treatment with oral isotretinoin.

Actas Dermosifiliogr

Retrospective case series of isotretinoin outcomes for acne in 393 female patients at Baylor College of Medicine during 2012-2016.

Investigation of relapse rate and factors affecting relapse after oral isotretinoin treatment in patients with acne vulgaris.

Dermatol Ther

Advantages of tailored isotretinoin treatment in moderate to severe acne: real-life data.

Front Pharmacol

Truven Health Analytics MarketScan databases for clinical research in colon and rectal surgery.

Clin Colon Rectal Surg

Big data in dermatology: publicly available health care databases for population health research.

Temporal trends in the use of systemic medications for acne from 2017 to 2020.

Anthropometric reference data for children and adults: United States, 2015-2018.

Vital Health Stat 3

Safety and efficacy of low-dose isotretinoin in the treatment of moderate to severe acne vulgaris.

Indian J Dermatol

Isotretinoin: dose, duration and relapse. What does 30 years of usage tell us?

A systematic review of isotretinoin dosing in acne vulgaris.

JEADV Clin Pract

Effectiveness of conventional, low-dose and intermittent oral isotretinoin in the treatment of acne: a randomized, controlled comparative study.

Differences in isotretinoin start, interruption, and early termination across race and sex in the iPLEDGE era.

PLoS One

The prevalence of acne in adults 20 years and older.

[Acne, hyperandrogenism and oral isotretinoin resistance. 23 cases. Therapeutic implications].

Ann Dermatol Venereol

Isotretinoin treatment in nodulocystic acne with and without polycystic ovary syndrome: efficacy and determinants of relapse.

Int J Dermatol

Acne accounts for an almost 2.5-fold higher proportion of dermatology visits among adult females compared to adult males in the United States: a study of the national ambulatory medical care survey from 2002-2016.

Making sense of the effects of the cumulative dose of isotretinoin in acne vulgaris.

Isotretinoin is the only medical acne treatment capable of inducing acne remission; however, some patients experience acne relapse and require retrials of isotretinoin. There is a need to understand who is most at risk and how daily dose and cumulative dosage can influence outcomes.
To assess rates of acne relapse and isotretinoin retrial and to identify associated factors among patients with acne who received an isotretinoin treatment course.
This cohort study used data from the MarketScan commercial claims database from January 1, 2017, to December 31, 2020, to identify patients with acne who were 12 years or older and had received isotretinoin for 4 months or longer, with at least 1 year of continuous enrollment after completion of isotretinoin. Data analyses were performed from June 30, 2024, to August 1, 2024.
Multivariable Cox proportional hazards regression was used to quantify associations of patient demographic and treatment characteristics with acne relapse and isotretinoin retrial.
A total of 19 907 patients (mean [SD] age, 20.6 [7.8] years; 10 504 females [52.8%]) were included, among whom 4482 (22.5%) had acne relapse and 1639 (8.2%) had isotretinoin retrial. Female sex (hazard ratio [HR], 1.43; 95% CI, 1.35-1.52) was significantly associated with increased rates of acne relapse, and isotretinoin cumulative dosage (mg/kg) was associated with a decreased rate of acne relapse (HR, 0.996; 95% CI, 0.995-0.997). Furthermore, daily dose was not associated with decreased risk of acne relapse or isotretinoin retrial among those with conventional and high cumulative dosages. Female sex (HR, 0.68; 95% CI, 0.62-0.76) and isotretinoin cumulative dosage (HR, 0.99; 95% CI, 0.98-0.99) were associated with decreased rates of isotretinoin retrial. Stratification by cumulative dosage indicated that higher cumulative dosage was associated with decreased rates of retrial among patients with low (<120 mg/kg) and conventional (120-220 mg/kg), but not high (>220 mg/kg) cumulative dosage. Maximum daily dose (mg/kg/d) was not negatively associated with acne relapse or isotretinoin retrial in patients with cumulative dosage of 120 mg/kg or more.
The findings of this cohort study suggest that higher cumulative dosage may potentially reduce risk of acne relapse and isotretinoin retrial. Furthermore, daily dose was not associated with decreased risk of the outcomes for conventional and high cumulative dosage; therefore, daily dosing could be individualized to patient goals and preferences.

Acne Relapse and Isotretinoin Retrial in Patients With Acne.

Acne Relapse and Isotretinoin Retrial in Patients With Acne

Acne Relapse and Isotretinoin Retrial in Patients With Acne

Clinical Summary

What was studied

Key findings

Clinical implications

Related Questions